arrow
L

Leyla Shune

Stanford University
H指数:25
被引数:2,493

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma

西达基奥仑赛注射液(ciltacabtagene autoleucel)在重度预治疗复发或难治性多发性骨髓瘤患者中引发的细胞减少症和感染

2026-01-014
OA
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

TSCM优势的异基因抗BCMA CAR-T疗法治疗复发/难治性多发性骨髓瘤:临床前表征和1期试验的初步结果

2025-11-240
OAAI
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response

多发性骨髓瘤患者对特克替玛初始无应答后延迟应答的预测因子

2025-10-110
OAAI
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium

氟达拉滨淋巴细胞清除暴露与伊达比特-维克鲁塞尔治疗后复发性/难治性多发性骨髓瘤的毒性相关:来自美国骨髓瘤免疫治疗联盟的真实世界经验

2025-09-170
PREAI
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia

BCMA定向嵌合抗原受体T细胞疗法治疗浆细胞白血病的有效性与安全性

2025-09-010
OAAI
Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey

移植适用新诊断多发性骨髓瘤的管理实践:一项基于美国的横断面全国调查

2025-07-090
PRE
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

接受过BCMA靶向疗法的复发/难治性多发性骨髓瘤患者中teclistamab的治疗效果:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-06-250
OAAI
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison

比较cilta-cabtagene autoleucel与标准护理治疗用于既往接受过治疗的复发或难治性多发性骨髓瘤患者的疗效:一项匹配调整间接比较研究

2025-05-120
OA
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the US Multiple Myeloma Immunotherapy Consortium

复发难治性多发性骨髓瘤(RRMM)老年患者接受teclistamab治疗后的结局:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-05-090
OA
Development of an Endothelial Activation and Stress Index (EASIX)-based predictive model for cytokine release syndrome and neurotoxicity after B-cell maturation antigen directed chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma

基于内皮激活和应激指数(EASIX)的预测模型开发:用于B细胞成熟抗原导向的嵌合抗原受体T细胞疗法后细胞因子释放综合征和神经毒性的预测,适用于复发/难治性多发性骨髓瘤。

2025-04-290
PRE
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

靶向BCMA或GPRC5D的双特异性抗体在CAR T细胞治疗后复发的骨髓瘤中非常有效

2024-12-050
OAAI
An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell

基于内皮激活和应激指数(EASIX)的预测模型,用于B细胞成熟抗原(BCMA)导向的嵌合抗原受体(CAR)T细胞疗法后的神经毒性及细胞因子释放综合征(CRS)

BLOOD
IF23.1
2024-11-050
PRE
The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

蒙特利尔认知评估在预测CD19和BCMA CART治疗后神经毒性中的应用

BLOOD
IF23.1
2024-11-050
PRE
Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

高压氧(HBO)对高剂量治疗和自体HSPC移植后多发性骨髓瘤患者血细胞计数恢复及移植结局的影响:多中心Ⅱ期随机临床试验的最终分析

BLOOD
IF23.1
2024-11-050
PRE
Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

干细胞增强(SCB)对嵌合抗原受体T细胞(CAR-T)相关血液学毒性的疗效:一项多中心真实世界研究经验(针对复发/难治性多发性骨髓瘤患者)

BLOOD
IF23.1
2024-11-050
PRE
Second Primary Malignancies after CAR T-Cell Therapy: A Systemic Review

CAR T细胞疗法后的第二原发恶性肿瘤:一项系统性综述

BLOOD
IF23.1
2024-11-050
PRE
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma

骨髓瘤CAR T治疗后毒性和非复发死亡率的时间

2024-09-019
OAAI